KJIM :: Korean Journal of Internal Medicine

A prognostic model incorporating inflammatory cells and cytokines for newly diagnosed multiple myeloma patients

Liang Ren, Jiadai Xu, Jing Li, Tianhong Xu, Yang Yang, Wenjing Wang, Yuhong Ren, Shiyang Gu, Chen Chen, Zheng Wei, Jingli Zhuang, Zhimei Wang, Lili Ji, Luya Cheng, Weiguang Wang, Zhixiang Cheng, Yang Ke, Ling Yuan, Peng Liu

Clinical and Experimental Medicine.2023; 23(6): 2583. CrossRef

Inflammatory and Nutritional Scoring System for Predicting Prognosis in Patients with Newly Diagnosed Multiple Myeloma

Limei Zhang, Shuzhao Chen, Weida Wang, Yun Wang, Yang Liang

Journal of Inflammation Research.2023; Volume 16: 7. CrossRef

Evaluation of angiopoietin-2 level in patients with multiple myeloma at presentation and in remission state

Iraqi Journal of Hematology.2023; 12(1): 8. CrossRef

Reduction rate of monoclonal protein as a useful prognostic factor in standard-risk group of newly diagnosed multiple myeloma

World Journal of Clinical Cases.2023; 11(24): 5643. CrossRef

The combination of serum calcium levels, neutrophil‑to‑lymphocyte ratio and platelet count in the prognosis of multiple myeloma: A retrospective cohort study and review of the literature

World Academy of Sciences Journal.2022;[Epub] CrossRef

Correlation between platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio with hematological parameters in multiple myeloma patients

AkankshaAshok Kalal, VijithVittal Shetty, KailkerePadma Shetty, Meenakshi Arumugam, ReshmaArun Shetty, NagarajVenkatesh Kulkarni, DeyyenthodyPrashanth Shetty

Biomedical and Biotechnology Research Journal (BBRJ).2022; 6(1): 132. CrossRef

Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients

Cristina Potre, Ema Borsi, Ovidiu Potre, Miruna Samfireag, Dan Costachescu, Bianca Cerbu, Felix Bratosin, Cristina Secosan, Rodica Anamaria Negrean

Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population‐based study from the Danish nati

Louise Redder, Tobias W. Klausen, Annette Juul Vangsted, Henrik Gregersen, Niels F. Andersen, Robert S. Pedersen, Agoston G. Szabo, Mikael Frederiksen, Ulf C. Frølund, Carsten Helleberg, Lene Kongsgaard Nielsen, Per T. Pedersen, Morten Salomo, Peter Gimsi

British Journal of Haematology.2021; 193(1): 119. CrossRef

Evaluation of the UK Myeloma Research Alliance Risk Profile in Chinese Patients with Newly Diagnosed Multiple Myeloma without Autologous Stem Cell Transplantation

Kewa Ma, Jiannan Ye, Lingling Wang, Chao Sun, Xin Zhou

OncoTargets and Therapy.2021; Volume 14: 2349. CrossRef

Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients

Are the Derived Indexes of Peripheral Whole Blood Cell Counts (NLR, PLR, LMR/MLR) Clinically Significant Prognostic Biomarkers in Multiple Myeloma? A Systematic Review And Meta-Analysis

Xinwen Zhang, Jialin Duan, Zhenyu Wen, Hao Xiong, Xiaomin Chen, Yang Liu, Kunyu Liao, Chunlan Huang

The Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios as New Prognostic Factors in Hematological Malignancies – A Narrative Review

Paulina Stefaniuk, Agnieszka Szymczyk, Monika Podhorecka

Cancer Management and Research.2020; Volume 12: 2961. CrossRef

Combined C-Reactive Protein and Novel Inflammatory Parameters as a Predictor in Cancer—What Can We Learn from the Hematological Experience?

Øystein Bruserud, Helene Hersvik Aarstad, Tor Henrik Anderson Tvedt

Bleeding diathesis in canine multiple myeloma and prognostic implications: A cohort study in 156 dogs

Marco Caldin, Michela Campigli, Andrea Zoia, Anna Zanella, Giovanna Bertolini, Tommaso Furlanello, George Lubas

Research in Veterinary Science.2019; 125: 305. CrossRef

Can Neutrophil‐to‐Lymphocyte Ratio, Monocyte‐to‐Lymphocyte Ratio, and Platelet‐to‐Lymphocyte Ratio at Day +100 be used as a prognostic marker in Multiple Myeloma patients with autologous transplantation?

Serife Solmaz Medeni, Celal Acar, Aybuke Olgun, Alev Acar, Ahmet Seyhanlı, Emin Taskıran, Omur Gokmen Sevindik, Inci Alacacıoglu, Ozden Piskin, Mehmet Ali Ozcan, Fatih Demirkan, Bulent Undar, Guner Hayri Ozsan

Association of CD117 and HLA‑DR expression with shorter overall survival and/or progression‑free survival in patients with multiple myeloma treated with bortezomib and thalidomide combination treatment without transplantation

Huan Wang, Xin Zhou, Jian‑Wei Zhu, Jian‑Nan Ye, Hong‑Feng Guo, Chao Sun